Hepatocellular Carcinoma

Electroporation-assisted gene therapy kills cells in primary liver cancer

Published in Hepatitis Weekly, March 4th, 2002

by Sonia Nichols, senior medical writer - Ligands that do not affect normal liver tissues can promote apoptosis in cancer cells when administered via electroporation-assisted gene therapy.

The latest of such studies has shown tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2 ligand (Apo2L)) gene therapy is effective in hepatocellular carcinoma (HCC), a primary form of liver cancer often resulting from cirrhosis, exposure to liver toxins, viral hepatitis, or other risk factors.

A new study conducted by Y. Yamashita and coauthors, Kyushu University, Japan, has revealed important information about the effects of TRAIL/Apo2L on HCC in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2002-03-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry